Optimal cervical cancer screening in women vaccinated against human papillomavirus

Journal of the National Cancer Institute

Volumn 109, Issue 2, 2017, Pages

  Kim, Jane J ^a   Burger, Emily A ^a,b   Sy, Stephen ^a   Campos, Nicole G ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 2; HUMAN PAPILLOMAVIRUS TYPE 4; HUMAN PAPILLOMAVIRUS TYPE 9; HUMAN TISSUE; MATHEMATICAL MODEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS; ADVERSE EFFECTS; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; ISOLATION AND PURIFICATION; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; TIME FACTOR; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; YOUNG ADULT;

ADULT; COLPOSCOPY; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; MODELS, THEORETICAL; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS; YOUNG ADULT;

EID: 85018691870     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw216     Document Type: Article

References (33)

1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172.
2. Moyer VA. Screening for Cervical Cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880-891.
3. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
4. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a doubleblind, randomised study in young women. Lancet. 2009;374(9686):301-314.
5. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147-2162.
6. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8): 711-723.
7. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-304.
8. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2014.MMWR Morb Mortal Wkly Rep. 2015;64(29):784-792.
9. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet. 2011;377(9783): 2085-2092.
10. Hariri S, Bennett NM, Niccolai LM, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine. 2015;33(13):1608-1613.
11. Hariri S, Markowitz LE, Dunne EF, Unger ER. Population impact of HPV vaccines: Summary of early evidence. J Adolesc Health. 2013;53(6):679-682.
12. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):1-9.
13. Campos NG, Burger EA, Sy S, et al. An updated natural history model of cervical cancer: Derivation of model parameters. Am J Epidemiol. 2014;180(5): 545-555.
14. Kim JJ, Campos NG, Sy S, et al. Inefficiencies and high-value improvements in US cervical cancer screening practice: A cost-effectiveness analysis. Ann Intern Med. 2015;163(8):589-597.
15. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: Critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315-324.
16. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008;26(37):4795-4808.
17. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190(12):2077-2087.
18. Wheeler CM, Hunt WC, Cuzick J, et al. A population-based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2013;132(1): 198-207.
19. Joste NE, Ronnett BM, Hunt WC, et al. Human papillomavirus genotypespecific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):230-240.
20. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-819.
21. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1-S27.
22. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Gynecol Oncol. 2015;136(2):178-182.
23. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. CDC vaccine price list. http://www.cdc.gov/vaccines/pro grams/vfc/awardees/vaccine-management/price-list/. Accessed March 14, 2016.
24. Stinnett AA, Paltiel AD. Estimating CE ratios under second-order uncertainty: The mean ratio versus the ratio of means. Med Decis Making. 1997;17(4): 483-489.
25. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9): 796-797.
26. Gold MR, Siegel JE, Russel LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
27. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus (HPV) DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008;100(5):308-320.
28. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290(6): 781-789.
29. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444-1451.
30. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol. 2015; 16(7):775-786.
31. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: Meta-analysis. BMJ. 2008;337:a1284.
32. Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: Event duration and health utility loss. Med Decis Making. 2007;27(4):414-422.
33. Korfage IJ, Essink-Bot ML, Westenberg SM, Helmerhorst T, Habbema JD, van Ballegooijen M. How distressing is referral to colposcopy in cervical cancer screening? A prospective quality of life study. Gynecol Oncol. 2014;132(1): 142-148.